|
Factors
|
N
|
%
|
|---|
|
Total
|
439
|
100
|
|
Age (years old)
|
|
Median (range)
|
73 (33–92)
|
|
Quartile
|
68 and 78
|
|
iPSA (ng/mL)
|
|
Median (range)
|
9.2 (1.6–24.0)
|
|
Quartile
|
6.3 and 14.7
|
|
Clinical T-stage
|
|
T1c
|
84
|
19.1
|
|
T2a
|
208
|
47.4
|
|
T2b
|
20
|
4.6
|
|
T2c
|
61
|
13.9
|
|
T3a
|
46
|
10.5
|
|
T3b
|
14
|
3.2
|
|
T4
|
6
|
1.4
|
|
Gleason score group
|
|
Group 1
|
46
|
10.5
|
|
Group 2
|
121
|
27.6
|
|
Group 3
|
117
|
26.7
|
|
Group 4
|
82
|
18.7
|
|
Group 5
|
73
|
16.6
|
|
Risk group
|
|
Low
|
21
|
4.8
|
|
Intermediate-low
|
84
|
19.1
|
|
Intermediate-high
|
149
|
33.9
|
|
High
|
112
|
25.5
|
|
Ver-high
|
73
|
16.6
|
|
Hormonal therapy
|
|
None
|
98
|
22.3
|
|
Short term
|
183
|
41.7
|
|
Long term
|
158
|
36.0
|
|
RT total dose
|
|
36.25 Gy
|
239
|
54.4
|
|
40 Gy
|
187
|
42.6
|
|
42.5 Gy
|
13
|
3.0
|
- PSA prostate-specific antigen, RT radiation therapy
